10-Q: Lifeloc Technologies Reports Q1 2025 Results: Revenue Up, SpinDx Development Continues

Lifeloc Technologies saw a 6% increase in product sales for Q1 2025 compared to Q1 2024, while continuing development of its SpinDx drug detection technology.

Summary

• Lifeloc Technologies, Inc. reported its financial results for the first quarter of 2025.
• Product sales increased by 6% to $2,263,047 compared to $2,134,434 in the same period last year.
• Total revenues, including royalties and rental income, rose by 6% to $2,277,034.
• The company experienced a net loss of $292,686, slightly higher than the net loss of $283,806 in Q1 2024.
• Research and development expenses remained high at $469,680, primarily related to the development of the SpinDx technology.
• The company expects to launch SpinDx commercially in 2026.
• Lifeloc issued two subordinated debentures in December 2024 and March 2025, totaling $825,000, to support operations and product development.
• The company anticipates discontinuing rental income after June 30, 2025, as the tenant's lease expires.
• Lifeloc believes that increased sales efforts and the expected availability of SpinDx may result in improved revenues in 2026 and beyond, but revenues in 2025 may be similar to revenues in 2024.
• The company believes that cash resources will be sufficient to fund operations for the next twelve months under the current operating plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While revenue increased, the company still experienced a net loss. The development of SpinDx is a positive sign, but its commercial launch is not expected until 2026. The company believes that cash resources will be sufficient to fund operations for the next twelve months under the current operating plan.

Positives

• Product sales increased by 6% compared to the same period last year, indicating growing demand for Lifeloc's products.
• Gross profit increased by 9%, suggesting improved efficiency or pricing strategies.
• The company is progressing with the development of SpinDx, which could provide a significant competitive advantage in the drug testing market.
• The company believes that cash resources will be sufficient to fund operations for the next twelve months under the current operating plan.

Negatives

• The company experienced a net loss of $292,686 for the quarter, indicating ongoing challenges with profitability.
• Research and development expenses remain high, reflecting the significant investment required for SpinDx development.
• The company expects to discontinue rental income after June 30, 2025, as the tenant's lease expires.
• The company is continuing to incur operating losses in 2025 and expects them to continue as it continues to work toward the commercialization of SpinDx.

Risks

• The company's future profitability is uncertain, and operating losses may continue.
• The development and market acceptance of SpinDx may take longer than expected, impacting revenue projections.
• Inflationary pressures could continue to affect the cost of raw materials, labor, and freight.
• The company's revenue fluctuations may continue due to the unpredictable timing of large orders from customers.
• If the company is not successful in sustaining profitability and remaining at least cash flow break-even, additional borrowings or capital may be required to maintain ongoing operations.

Future Outlook

Lifeloc anticipates increased sales efforts and the commercial launch of SpinDx in 2026 may lead to improved revenues in 2026 and beyond, but revenues in 2025 may be similar to revenues in 2024. The company believes that cash resources will be sufficient to fund operations for the next twelve months under the current operating plan.

Management Comments

• With the introduction of new products, we believe Lifeloc will again be profitable.
• We believe the installed base of our breathalyzers will increase as the inherent risks associated with drinking while driving or while working in safety sensitive jobs become more widely acknowledged and as our network of distributors and our direct sales force grows.

Industry Context

Lifeloc operates in the competitive alcohol and drug testing market. The company's focus on developing SpinDx technology aligns with the growing demand for accurate and rapid drug detection solutions, particularly in the context of marijuana impairment. The company competes in all major segments of the portable breath alcohol testing instrument market, including law enforcement, workplace, corrections, and original equipment manufacturing ('OEM') markets.

Comparison to Industry Standards

• It is difficult to compare Lifeloc's results directly to industry standards without specific data on competitors' performance.
• However, the company's focus on innovation, particularly with SpinDx, suggests an effort to differentiate itself in the market.
• Companies like Drägerwerk AG & Co. KGaA and Intoximeters, Inc. are major players in the breath alcohol testing market, and Lifeloc's performance can be benchmarked against their reported results and market share.
• The development of SpinDx is a unique advantage over competitors by isolating psychoactive delta-9-THC from its inactive metabolites, enabling more accurate impairment detectionespecially critical for marijuana testing where competitive devices may yield false positives from non-impairing compounds.

Related Party Transactions

• In February 2025 options to purchase 88,500 shares of our common stock were exercised at a price of $ 3.80 per share for total proceeds of $ 336,300 .
• Our president and CEO exercised 37,500 options, and 2 directors exercised 1,000 options each.
• EDCO Partners, LLLP, of which our CFO and board chairman is the general partner provided $ 132,240 to enable 19 option holders to exercise and simultaneously sell their shares to EDCO Partners, to be held on behalf of certain of its limited partners, including a third director and an entity controlled by our CFO and board chairman.

Stakeholder Impact

• Shareholders: The net loss may concern shareholders, but the revenue growth and SpinDx development could be seen as positive signs.
• Employees: The company's focus on growth and new product development could provide opportunities for employees.
• Customers: The development of SpinDx could lead to more accurate and reliable drug testing solutions for customers.
• Suppliers: The company's efforts to manage inflationary pressures could impact its relationships with suppliers.
• Creditors: The issuance of subordinated debentures increases the company's debt obligations.

Next Steps

• Continue development and testing of SpinDx technology.
• Prepare for commercial launch of SpinDx in 2026.
• Focus on growing sales and increasing gross profits.
• Manage inflationary pressures and mitigate their impact on the business.
• Monitor cash flow and ensure sufficient resources to fund operations.

Key Dates

Keywords

SpinDx, breathalyzers, alcohol testing, drug testing, revenue, net loss, Lifeloc Technologies, financial results, Q1 2025